Spark Newswire Spark Newswire
  • Newswire
  • News
    • Guidance
    • Dividends
    • M&A
    • Buybacks
    • Legal
    • Interviews
    • Management
    • Offerings
    • IPOs
    • Insider Trades
    • Biotech/FDA
    • Tech
  • Markets
    • After Hours
    • Movers
    • ETFs
    • Forex
    • Commodities
    • Options
    • Binary Options
    • Bonds
    • Futures
    • Global Economics
    • Reviews
    • Small-Cap
    • Cryptocurrency
    • Penny Stocks
  • Analysts
    • Analyst Color
    • Analyst Ratings
    • Upgrades
    • Downgrades
  • Earnings
    • Earnings
  • Support & Feedback
  • Registration Options
  • Log In
News by Category
  • After-Hours Center
  • Analyst Color
  • Analyst Ratings
  • Asia
  • Asset Sales
  • Binary Options
  • Biotech
  • Bonds
  • Broad U.S. Equity ETFs
  • Buybacks
  • Cannabis
  • Commodities
  • Contracts
  • Crowdsourcing
  • Cryptocurrency
  • Currency ETFs
  • Dividends
  • Downgrades
  • Earnings
  • Earnings Beats
  • Earnings Misses
  • Econ #s
  • Economics
  • Education
  • Emerging Market ETFs
  • Emerging Markets
  • Entertainment
  • Entrepreneurship
  • Equities
  • ESG
  • ETFs
  • Eurozone
  • Events
  • Exclusives
  • FDA
  • Federal Reserve
  • Financial Advisors
  • Financing
  • Fintech
  • Forex
  • Futures
  • Gaming
  • General
  • Global
  • Government
  • Guidance
  • Health Care
  • Hedge Funds
  • Hot
  • Initiation
  • Insider Trades
  • Insurance
  • Interview
  • Intraday Update
  • IPOs
  • Large Cap
  • Latin America
  • Legal
  • Long Ideas
  • M&A
  • Macro Economic Events
  • Macro Notification
  • Management
  • Market Summary
  • Market-Moving Exclusives
  • Markets
  • Media
  • Mid Cap
  • Mining
  • Movers
  • Movers & Shakers
  • Mutual Funds
  • New ETFs
  • News
  • Offerings
  • Opinion
  • Options
  • Penny Stocks
  • Personal Finance
  • Politics
  • Pre-Market Outlook
  • Press Releases
  • Previews
  • Price Target
  • Psychedelics
  • Psychology
  • Real Estate
  • Regulations
  • REIT
  • Reiteration
  • Restaurants
  • Retail Sales
  • Reviews
  • Rumors
  • SEC
  • Sector ETFs
  • Short Ideas
  • Short Sellers
  • Signals
  • Small Business
  • Small Cap
  • Small Cap Analysis
  • Small-Cap
  • Social Media
  • SPACE
  • Specialty ETFs
  • Sports
  • Sports Betting
  • Startups
  • Stock Split
  • Success Stories
  • Tech
  • Technicals
  • Termination
  • Top Stories
  • Topics
  • Trading Ideas
  • Travel
  • Treasuries
  • Uncategorized
  • Upgrades
Spark Newswire Spark Newswire
Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.
  • Newswire
  • News
    • Guidance
    • Dividends
    • M&A
    • Buybacks
    • Legal
    • Interviews
    • Management
    • Offerings
    • IPOs
    • Insider Trades
    • Biotech/FDA
    • Tech
  • Markets
    • After Hours
    • Movers
    • ETFs
    • Forex
    • Commodities
    • Options
    • Binary Options
    • Bonds
    • Futures
    • Global Economics
    • Reviews
    • Small-Cap
    • Cryptocurrency
    • Penny Stocks
  • Analysts
    • Analyst Color
    • Analyst Ratings
    • Upgrades
    • Downgrades
  • Earnings
    • Earnings
  • Support & Feedback
  • Registration Options
  • Log In
Spark Newswire Spark Newswire
Filter By Ticker
Search By Date To
Today | Yesterday | This week
Browsing Category

Health Care

Health Care

Group By Ticker
Sort By
Newest | Oldest
Read More
2 minute read
  • Equities
  • General
  • Health Care
  • Large Cap
  • Markets
  • Media
  • News

Sandoz Pushes Product Launch Plans As Novartis Shareholders Approve The Spin-Off

By Vandana Singh
September 15, 6:54 AM
At an Extraordinary General Meeting, Novartis AG's (NYSE: NVS) shareholders 

JNJ

Read More
1 minute read
  • General
  • Health Care
  • Large Cap
  • Legal
  • News

Lawsuit Against Dummy Pills For Allergy, Cold: Johnson & Johnson And Procter & Gamble Face Allegations

By Vandana Singh
September 14, 3:10 PM
In a recent lawsuit, Johnson & Johnson (NYSE: JNJ) and Procter & Gamble Co (NYSE: PG) are facing allegations of misleading consumers regarding decongestant cold medicines conta

JNJ

Read More
2 minute read
  • Analyst Color
  • Analyst Ratings
  • Biotech
  • Equities
  • General
  • Health Care
  • Markets
  • News
  • Price Target
  • Reiteration
  • Trading Ideas

Potential Label Restrictions Loom For Alnylam’s Patisiran Despite Approval Prospects

By Vandana Singh
September 14, 3:00 PM
On Wednesday, an FDA advisory committee voted 9-3 in favor of Alnylam Pharmaceuticals Inc's (NASDAQ: ALNY) patisiran.

ALNY

Read More
1 minute read
  • Biotech
  • General
  • Health Care
  • Large Cap
  • News

Bristol-Myers Squibb Plans To Double Clinical Pipeline Platforms To Support Long-Term Sustainable Growth

By Vandana Singh
September 14, 1:53 PM
Bristol-Myers Squibb & Co (NYSE: BMY) announced its ambitious plan to double the number of treatments undergoing clinical trials in the next 18 months, focusing primarily on targeted protein 

BMY

Read More
1 minute read
  • Analyst Color
  • Analyst Ratings
  • Biotech
  • General
  • Health Care
  • Large Cap
  • News
  • Trading Ideas

Moderna’s R&D Day Unveils Strategic Roadmap Beyond COVID Franchise: Goldman Sachs

By Vandana Singh
September 14, 1:23 PM
On Wednesday, Moderna Inc (NASDAQ: MRNA) conducted an R&D Day event outlining its strategic initiatives across four key areas - Respiratory Vaccines, Latent/Other Vaccines, Oncology Therapeutics, 

GSK

Read More
1 minute read
  • Biotech
  • General
  • Health Care
  • Movers
  • News
  • Penny Stocks

Why Is Immuno-Oncology Firm Harpoon Therapeutics Stock Trading Lower Today?

By Vandana Singh
September 14, 11:31 AM
Harpoon Therapeutics Inc (NASDAQ: HARP) shares are trading lower after AbbVie Inc (NYSE: ABBV) chose not to exercise its exclusive license option within the Development and Option Agreement regarding <

ABBV

Read More
1 minute read
  • Biotech
  • FDA
  • General
  • Health Care
  • Movers
  • News
  • Trading Ideas

Despite FDA Doubts, Adcomm Backs Alnylam’s Gene Silencing Therapy For Expanded Use Into Rare Heart Disease

By Vandana Singh
September 14, 7:26 AM
On Wednesday, an FDA advisory committee voted 9-3 in favor of Alnylam Pharmaceuticals Inc's (NASDAQ: ALNY) patisiran.

ALNY

Read More
2 minute read
  • Biotech
  • Contracts
  • General
  • Health Care
  • Large Cap
  • News
  • Penny Stocks

‘Transformative Event’ For First Wave BioPharma: License Agreement for Hopeful Gastrointestinal Candidate From Sanofi

By Vandana Singh
September 14, 6:00 AM
First Wave BioPharma Inc (NASDAQ: FWBI) announced an agreement with Sanofi SA (NASDAQ: SNY) to license Capeserod, a selective 5-HT4 receptor partial agonist, which First Wave will repurpose and develop for

FWBI

Read More
1 minute read
  • Analyst Color
  • Analyst Ratings
  • Biotech
  • Downgrades
  • Equities
  • General
  • Health Care
  • Markets
  • Movers
  • News
  • Penny Stocks
  • Trading Ideas

2seventy Bio’s Cost Cuts Prudent But Analyst Says It Induces Lower Confidence In Lead Product

By Vandana Singh
September 13, 3:25 PM
Guggenheim Partners downgraded 2seventy Bio Inc (NASDAQ: TSVT) to Neutral from Buy and 

TSVT

Read More
1 minute read
  • Analyst Color
  • Analyst Ratings
  • Biotech
  • Equities
  • General
  • Health Care
  • Initiation
  • Markets
  • News
  • Price Target
  • Trading Ideas

Cancer Focused Immunocore Leads The Way In TCR Therapeutics, Positioned For Success: Analyst Says

By Vandana Singh
September 13, 2:32 PM
Needham has initiated coverage on Immunocore Holdings Plc (NASDAQ: IMCR) with a Buy rating and 

IMCR

Posts pagination

Previous 1 … 163 164 165 … 478 Next
Free Newsletter subscribe

Stock Market Ideas & Analysis

Stay up-to-date with the same information professionals use.
Spark Newswire Spark Newswire
  • Newswire
  • Registration
  • Log In
  • Settings
  • Privacy Policy
  • Terms of Service
© 2021 Spark Newswire
All Rights Reserved.

All news is property of their respective owners. Terms of Service